Investor News no. 02/2019
To: NASDAQ Copenhagen A/S
Copenhagen, Denmark, 1 May 2019
Veloxis to Host Conference Call Following Release of Interim Financial Report for the Period 1 January to 31 March 2019
Veloxis Pharmaceuticals A/S (NASDAQ: VELO) will release its Interim Report for the first quarter 2019 on Monday, May 6, 2019.
In connection with the release, Veloxis’s Executive Management will host a conference call to discuss the financial results on Tuesday, May 7, 2019 at 4:00 p.m. CET (Denmark); 3:00 p.m. GST (London); and 10:00 a.m. EST (New York).
To access the live conference call, please dial one of the following numbers:
+1 917 720 0178 (USA)
+45 32 72 75 18 (Denmark)
+44 (0) 203 009 5710 (UK)
Confirmation Code: 7877813
Following the conference call, a recording will be available on the Company’s website: http://www.veloxis.com.
For more information, please contact:
|Craig A. Collard||Ira Duarte|
|President & CEO||CFO|
|Phone: + 1 919 591 3090||Phone: +1 919 591 3090|
|Email: email@example.com||Email: firstname.lastname@example.org|
About Veloxis Pharmaceuticals
Veloxis Pharmaceuticals A/S is a commercial-stage specialty pharmaceutical company committed to improving the lives of transplant patients. A Danish company, Veloxis Pharmaceuticals A/S operates in the U.S. through Veloxis Pharmaceuticals Inc., a wholly-owned subsidiary headquartered in Cary, North Carolina, USA. Veloxis has successfully developed Envarsus XR (tacrolimus extended-release tablets) based upon the company’s unique and patented delivery technology, MeltDose®, which is designed to enhance the absorption and bioavailability of select orally administered drugs. The company is focused on the direct commercialization of Envarsus XR in the U.S., expansion of partnerships for markets around the world, and acquisition of assets utilized in transplant patients and by adjacent medical specialties. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.
For further information, please visit www.veloxis.com.